Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference

TORONTO, ON / ACCESSWIRE / September 8, 2022 / Edesa Biotech, Inc. (NASDAQ: EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference being held in New York, NY on September 12-14, 2022.

Edesa Presentation Details

Date: September 12, 2022
Time: 10:00 am Eastern Time
Presentation Slides: Available in the events section of the Edesa website.

Attendees who are interested in meeting with the company should contact their H.C. Wainwright representative or Edesa directly via email at [email protected].

About Edesa Biotech, Inc.

Edesa Biotech, Inc. (NASDAQ: EDSA) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that Edesa is developing as a treatment for Acute Respiratory Distress Syndrome (ARDS). Edesa is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. Sign up for news alerts. Connect with Edesa Biotech on Twitter and LinkedIn.

Contact

Gary Koppenjan
Edesa Biotech, Inc.
(805) 488-2800 ext. 150
[email protected]

SOURCE: Edesa Biotech

You May Also Be Interested In

• PayPoint plc : Director/PDMR Shareholding
• Lemkin Family and European Jewish Association Call on Pennsylvania and Federal Officials to Investigate Institute Bearing Raphael Lemkin’s Name
• Strathmore Announces Drilling Plans for Beaver Rim in the Prolific Gas Hills District